Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

Background An updated systematic review and meta‐analysis of relevant studies to
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …

Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …

Purpose Preliminary data from retrospective analyses and recent data from large
randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) …

Purpose The currently used scheme for radioligand therapy (RLT) of patients with metastatic
castration-resistant prostate cancer (mCRPC) consists of 4–6 cycles of 6.0–7.4 GBq [177Lu] …

The use of 225Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand
therapy (RLT), either as monotherapy or in combination with 177Lu, is a promising therapy …

Cadmium-contaminated water and food are seriously hazardous to the human health,
especially liver injury. To understand the entanglement relationship between cadmium ion …

The aim of the review was to evaluate patient and treatment characteristics for patients with
metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand …

Background The presence of visceral metastases is associated with poor prognosis in
patients of metastatic castration-resistant prostate cancer (mCRPC) treated with hormonal …